Swiss medtech SME developing NMR-based quantitative embryo assessment systems to improve IVF success rates.
Annaida Technologies is a Swiss medtech SME developing Embryospin, a non-invasive nuclear magnetic resonance (NMR) system that transforms embryo selection in IVF from subjective visual grading to objective, quantitative measurement. Their core technology applies NMR spectroscopy to assess embryo viability before implantation, giving fertility clinics a data-driven basis for selecting the embryo most likely to result in a successful pregnancy. They progressed from a Phase 1 feasibility study in 2018 to a full Phase 2 commercialization project by 2021, indicating an active path from research prototype to market-ready medical device. Their work sits at the intersection of reproductive medicine, analytical chemistry, and medical device engineering.
Both Embryospin projects (2018 and 2021) are built on applying nuclear magnetic resonance to quantify embryo biological markers, making NMR instrumentation and signal analysis their core technical competence.
The Embryospin concept — replacing qualitative embryo grading with quantitative NMR readouts — is the single consistent focus across both H2020 projects spanning 2018 to 2023.
The SME-2 Embryospin project (EUR 1.6M, 2021-2023) signals a transition from proof-of-concept to full-scale product development and market entry preparation.
Annaida's H2020 trajectory is not a shift in direction but a deliberate deepening of a single product thesis. Their 2018 Phase 1 project (EUR 50,000) established feasibility for NMR-based embryo quantification, with no publicly indexed keywords — typical of an early-stage concept validation. By 2021, their Phase 2 project (EUR 1.6M) crystallized around the specific terms "Embryo Assessment", "Nuclear Magnetic Resonance", and "IVF", reflecting a mature, defined product ready for clinical validation and commercialization. The trajectory is linear: one technology, one application, progressively larger investment and ambition.
Annaida is on a commercialization path for a single, highly specialized medtech product — future partnerships are most likely with IVF clinic networks, fertility diagnostics companies, or medical device distributors rather than broad research consortia.
Annaida operates exclusively as a project coordinator and appears to work in very small, tightly focused teams — their two projects involve only one unique partner across one country. This is consistent with a product-focused SME running EU-funded R&D internally rather than building broad academic or industrial networks. Working with them likely means engaging with a technically deep but narrowly specialized team that drives its own agenda rather than slotting into someone else's consortium.
Annaida has collaborated with just one partner organization in one country across both projects — an exceptionally small network footprint. This reflects the self-contained nature of SME Instrument funding, which is designed for single-company innovation rather than multi-partner research.
Annaida holds a rare position at the intersection of NMR instrumentation and reproductive medicine — a combination with almost no direct competitors in the EU project landscape. Their completed progression from SME Phase 1 to Phase 2 means they have both validated the concept and secured substantial EU backing, which is a credibility signal for clinical partners or investors considering engagement. For any consortium working on fertility diagnostics, reproductive health technology, or point-of-care analytical devices, they bring a finished technology track record rather than early-stage speculation.
